Literature DB >> 14618619

Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.

Robin S Treichel1, Michael Bunuan, Nancy Hahn, Kathleen Wee.   

Abstract

Most leukemias that exhibit P-glycoprotein (P-gp)-associated multidrug resistance (MDR) exhibit reduced susceptibility to immune cytotoxicity mediated by natural killer (NK) cells. To explore this phenomenon we investigated N6/ADR, a doxorubicin-selected, P-gp-positive variant of the human acute lymphoblastic leukemia (ALL) cell line NALM6. Each stage of the NK cytolytic pathway, (binding, activation and killing) was evaluated to identify the alterations responsible for the reduced cytotoxicity of the variant relative to its drug-sensitive parental line. The major cause of the decreased susceptibility to NK cytolysis was found to be reduced conjugate formation by the MDR variant. Activation of NK effectors by parental and MDR cells with concomitant release of tumor necrosis factor-alpha (TNF-alpha) correlated with conjugate formation. N6/ADR was also more resistant than NALM6 to antibody-dependent cellular cytotoxicity and to cytotoxic factors released from NK cells as measured both by 51Cr-release and by DNA fragmentation. This is the first report of a P-gp-positive leukemic line that exhibits reduced conjugate formation as well as increased resistance to NK-mediated killing mechanisms. Our results suggest caution in the use of NK-based immunotherapy as an alternative treatment for multidrug-resistant leukemias. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14618619     DOI: 10.1002/ijc.11555

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

Authors:  Arash Nanbakhsh; Cécile Pochon; Aude Mallavialle; Sophie Amsellem; Jean Henri Bourhis; Salem Chouaib
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

Review 2.  Immunotherapy: a useful strategy to help combat multidrug resistance.

Authors:  Tyler J Curiel
Journal:  Drug Resist Updat       Date:  2012-04-05       Impact factor: 18.500

3.  Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.

Authors:  Henry Ogbomo; Martin Michaelis; Denise Klassert; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

4.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

5.  miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.

Authors:  Arash Nanbakhsh; Géraldine Visentin; Daniel Olive; Bassam Janji; Eugenie Mussard; Philippe Dessen; Guillaume Meurice; Yanyan Zhang; Fawzia Louache; Jean-Henri Bourhis; Salem Chouaib
Journal:  Oncoimmunology       Date:  2015-10-16       Impact factor: 8.110

6.  Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.

Authors:  Margaret E Macy; Deborah DeRyckere; Lia Gore
Journal:  Invest New Drugs       Date:  2010-11-03       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.